Krystal Biotech, Inc. (KRYS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Core Viewpoint - The presentation focuses on the strategic vision and objectives of Krystal Biotech for the next five years, highlighting the recent launch of VYJUVEK for treating dystrophic epidermolysis bullosa [3][5]. Group 1: Company Overview - Krystal Biotech is led by CEO and Chairman Krish Krishnan and President of R&D Suma Krishnan, who are presenting at a healthcare investment banking conference [2]. - The presentation is structured into two parts: a strategic overview by the CEO and specific deliverables by the President of R&D [3]. Group 2: Product Launch - VYJUVEK was launched in September 2023, aimed at treating patients with dystrophic epidermolysis bullosa, showcasing its differentiated nature in the market [5].